Investor Presentation H1 2023
138
Investor presentation
First six months of 2023
North America Operations at a glance.
NAO
Diabetes trend in population
Million
DKK
billion
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
First half of
2023
Sales
(MDKK)
Growth²
589
70
60
50
40
30
20
10
4320
0
2021
63
57
ון
51
10%
11%
900
Injectable GLP-13
30,861
43%
80%
RybelsusⓇ
4,933
56%
Total GLP-1
35,794
44%
60%
600
Total insulin4
5,284
-25%
89
GLP-1
Other Diabetes care5
301
-22%
40%
45.7%¹
Diabetes care
41,379
28%
300
2.3%1
Insulin
Obesity care
14159
207%
20%
Diabetes & Obesity
OAD
55,538
51%
17.7%1
care
0
0%
2030
2045
May
2018
May
2023
Rare disease?
Total
3,422
-18%
58,960
44%
Population with diabetes
Diabetes growth rate
-GLP-1 MS
-Insulin MS
OAD MS
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of May 2023: Novo Nordisk 43%,
Others 58%; Competitor GLP-1 value market shares, as of May 2023: Novo
Nordisk 52%, Others 48%. OAD: Oral anti-diabetic; MS: Market Share; Source:
IQVIA MAT, May 2023 value figures
2 At constant exchange rates; ³ Comprises VictozaⓇ, Ozempic®;
4 Comprises Tresiba®, XultophyⓇ, Levemir®, NovoMix®, Fiasp® and NovoRapidⓇ;
5Comprises Novo NormⓇ and needles; 6 Comprises SaxendaⓇ and WegovyⓇ
7Comprises primarily NovoSeven®, Novo Eight® Esperoct®, NovoThirteen®,
Refixia®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation